PRESS RELEASE

Stockholm, Sweden, 31 August 2017



New number of shares and votes in Swedish Orphan Biovitrum AB (publ)

As per 31 August 2017, the total number of shares in <u>Swedish Orphan Biovitrum AB (publ)</u> amounts to 272,507,708. All shares are common shares. The total number of votes are 272,507,708. The increase in the number of shares and votes results from an issue of 496,760 class C shares. The class C shares are intended to ensure fulfilment of commitments under incentive programmes. The newly issued class C shares as well as the 1,621,178 class C shares previously held by the company have by virtue of the conversion clause in the articles of association been converted to common shares. As per 31 August 2017 the company holds 3,383,739 common shares.

About Sobi™

Sobi™ is an international speciality healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on Haemophilia, Inflammation and Genetic diseases. We also market a portfolio of speciality and rare disease products across Europe, the Middle East, North Africa and Russia for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2016, Sobi had total revenues of SEK 5.2 billion (USD 608 M) and approximately 760 employees. The share (STO:SOBI) is listed on Nasdaq Stockholm. More information is available at www.sobi.com.

For more information please contact

linda.holmstrom@sobi.com

Media relations Linda Holmström, Senior Communications Manager +46 70 873 40 95 Investor relations
Jörgen Winroth, Vice President, Head of Investor Relations
+1 347 224 0819, +1 212 579 0506
jorgen.winroth@sobi.com

The above information has been made public in accordance with the Swedish Financial Instruments Trading Act. The information was released for public distribution on 31 August 2017 at 8:00 am CET.